Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark C Poznansky

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|September 19, 2007
Generation of a tissue-engineered thymic organoidFabrizio Vianello, Mark C Poznansky
Trends in Cell Biology|May 13, 2008
Reverse leukocyte migration can be attractive or repulsiveAnna Huttenlocher, Mark C Poznansky
The Oncologist|January 14, 2012
Vaccination of oncology patients: an effective tool and an opportunity not to be missedCamille N Kotton, Mark C Poznansky
Cell Reports. Medicine|January 14, 2022
Q fever vaccine development: Challenges and progress in balancing safety and efficacyAnn E Sluder, Mark C Poznansky
Methods in Molecular Biology (Clifton, N.J.)|April 10, 2010
Methods for quantitation of leukocyte chemotaxis and fugetaxisFabrizio Vianello, Elda Righi, Mark C Poznansky
Journal of Vaccines & Vaccination|April 23, 2016
Classification of Laser Vaccine AdjuvantsSatoshi Kashiwagi, Timothy Brauns, Mark C Poznansky
Journal of Molecular Medicine (Berlin, Germany)|September 6, 2005
Fugetaxis: active movement of leukocytes away from a chemokinetic agentFabrizio Vianello, Ivona T Olszak, Mark C Poznansky
Current HIV Research|February 3, 2007
Immune responses to HIV Gp120 that facilitate viral escapeLiljana Stevceva, Victor Yoon, Daphne Anastasiades, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Laser vaccine adjuvants. History, progress, and potentialSatoshi Kashiwagi, Timothy Brauns, Jeffrey Gelfand, et al.
Pharmacological Research|June 17, 2020
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agentJingzhe Wang, Bakhos A Tannous, Mark C Poznansky, et al.
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Methods in Molecular Biology (Clifton, N.J.)|September 19, 2007
Generation of a tissue-engineered thymic organoidFabrizio Vianello, Mark C Poznansky
Trends in Cell Biology|May 13, 2008
Reverse leukocyte migration can be attractive or repulsiveAnna Huttenlocher, Mark C Poznansky
The Oncologist|January 14, 2012
Vaccination of oncology patients: an effective tool and an opportunity not to be missedCamille N Kotton, Mark C Poznansky
Cell Reports. Medicine|January 14, 2022
Q fever vaccine development: Challenges and progress in balancing safety and efficacyAnn E Sluder, Mark C Poznansky
Methods in Molecular Biology (Clifton, N.J.)|April 10, 2010
Methods for quantitation of leukocyte chemotaxis and fugetaxisFabrizio Vianello, Elda Righi, Mark C Poznansky
Journal of Vaccines & Vaccination|April 23, 2016
Classification of Laser Vaccine AdjuvantsSatoshi Kashiwagi, Timothy Brauns, Mark C Poznansky
Journal of Molecular Medicine (Berlin, Germany)|September 6, 2005
Fugetaxis: active movement of leukocytes away from a chemokinetic agentFabrizio Vianello, Ivona T Olszak, Mark C Poznansky
Current HIV Research|February 3, 2007
Immune responses to HIV Gp120 that facilitate viral escapeLiljana Stevceva, Victor Yoon, Daphne Anastasiades, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Laser vaccine adjuvants. History, progress, and potentialSatoshi Kashiwagi, Timothy Brauns, Jeffrey Gelfand, et al.
Pharmacological Research|June 17, 2020
CXCR4 antagonist AMD3100 (plerixafor): From an impurity to a therapeutic agentJingzhe Wang, Bakhos A Tannous, Mark C Poznansky, et al.
Pageof 11